← Leaderboards
Eugenia V Broude
University Of South Carolina At Columbia
$2,038,170
Attributed
$3,985,648
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,985,648 · 5
By mechanism
R01$2,396,222 · 1
P20$889,433 · 2
R43$699,993 · 2
Top collaborators
- Hexin Chen4 shared
- Igor B Roninson3 shared
- Mengqian Chen2 shared
- Donald C. Porter1 shared
Most similar at University Of South Carolina At Columbia
Same institution · by research overlap
- Hexin Chen$2,168,038
- Peisheng Xu$5,773,962
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoGenetic TranscriptionCellsCell LineDrug TargetingPharmaceutical PreparationsMalignant Breast NeoplasmClinical DevelopmentTumorPreventSignal TransductionPhosphotransferasesResistanceResistance DevelopmentTranscription FactorKinase InhibitorBreast Cancer Cell LineLapatinibErbb2 GenePre-ClinicalGene ExpressionBaseProgramsAntineoplastic Agents
Grant awards (10)
Preventing adaptive drug resistance through Mediator kinase inhibition$609,336
R01 · FY2025 · CA
Preventing adaptive drug resistance through Mediator kinase inhibition$582,679
R01 · FY2024 · CA
Preventing adaptive drug resistance through Mediator kinase inhibition$596,858
R01 · FY2023 · CA
Preventing adaptive drug resistance through Mediator kinase inhibition$607,349
R01 · FY2022 · CA
Preventing in vivo resistance to PI3K/AKT/mTOR inhibitors through Mediator kinase inhibition$400,000
R43 · FY2022 · CA
Potentiating targeted drugs in breast cancer via transcription-regulating kinases$223,500
P20 · FY2019 · GM · contact PI
Selective Targeting of Phosphodiesterase 11A Transcription and Catalytic Activit$219,750
P20 · FY2018 · GM · contact PI
CDK8/19 inhibitor for the treatment of HER2+ breast cancer$299,993
R43 · FY2017 · CA
Selective Targeting of Phosphodiesterase 11A Transcription and Catalytic Activit$222,223
P20 · FY2017 · GM · contact PI
Selective Targeting of Phosphodiesterase 11A Transcription and Catalytic Activit$223,960
P20 · FY2016 · GM · contact PI